ARWR vs BBIO
ARWR: Arrowhead Pharmaceuticals is a clinical-stage biotechnology company leveraging its proprietary RNA interference (RNAi) platform to develop potent medicines that silence disease-causing genes. BBIO: BridgeBio is a portfolio-based biotech firm focused on translating genetic science into precision therapies for patients with severe genetic disorders.
Side-by-side fundamentals
| Metric | ARWR | BBIO | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $58.92 | $67.55 | |
| Market cap | $8.3B | $13.2B | |
| Net margin FY2025, SEC XBRL | -0.2% | -146.0% | ARWR higher |
| Operating margin FY2025, SEC XBRL | +11.9% | -104.2% | ARWR higher |
| ROE FY2025, SEC XBRL | -0.3% | n/a | |
| ROA FY2025, SEC XBRL | -0.1% | -78.3% | ARWR higher |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +126.3% | |
| Revenue CAGR (3y) SEC XBRL | +50.5% | +86.3% | BBIO higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.70 | 1.05 | |
| 1-year return as of 2026-10-20 close | +53.2% | +20.1% | ARWR higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.